June Bio
June Bio produces mucins—the complex glycoproteins that form the backbone of mucosal barriers—at industrial scale to restore the body's first line of defense. Its mucin-based products block pathogen adhesion, suppress virulence gene expression, modulate inflammatory signaling, and nourish beneficial gut bacteria. The company targets biopharmaceutical and nutritional product developers addressing inflammatory, infectious, and microbiome-related conditions.
- Biotechnology
- Healthcare Technology
- Drug Discovery & Therapeutics
Funding
Founders
Founder details are not available yet.
Product
Problem
Mucosal surfaces cover more than 100 m² of the human body, forming a living shield that shapes immunity, defends against pathogens, and enables essential functions from breathing to digestion. When these barriers fail—due to inflammation, infection, or chronic disease—patients experience serious health consequences, yet current therapeutic approaches fail to address the underlying structural breakdown of the mucosal layer itself.
Solution
June Bio enables scalable, affordable production of mucins, the complex glycoproteins that form the backbone of mucosal barriers. By manufacturing these molecules at industrial scale, the company unlocks new ways to restore and strengthen the body's first line of defense. The company's mucin-based products form a physical barrier that prevents bacteria, yeasts, and viruses from reaching the underlying epithelium; downregulate pathogen virulence gene expression; modulate inflammatory signaling to prevent excessive immune activation; and provide glycans that nourish beneficial gut bacteria. This foundational approach powers a new generation of products and therapies that restore mucosal health at its biological origin rather than merely treating downstream symptoms.
Target Audience
Primary customers are biopharmaceutical companies, nutritional product developers, and clinical researchers developing therapies for inflammatory, infectious, and microbiome-related conditions affecting mucosal surfaces.
Features
- Scalable biomanufacturing platform for complex mucin glycoproteins, making production affordable and commercially viable
- Mucins that act as a physical filter and shield, preventing pathogen adhesion to epithelial surfaces
- Virulence suppression through downregulation of pathogen gene expression, strengthening gut resilience
- Immune modulation via interaction with immune cells to dampen inflammation and guard against chronic immune dysregulation
- Glycan-based support for the mucosal microbiome, nourishing beneficial bacteria and promoting metabolite production that strengthens epithelial and immune health
- Integration of glycobiology, biomanufacturing, and immunology expertise across the product development pipeline